Science for People
IGEN BIOLAB GROUP brings microbiome science to the discovery and development of new therapeutic products.
Igen Biolab Group
IGEN BIOLAB GROUP has established a pipeline of microbiome modulators in clinical phase development that impact in the prevention and treatment of diseases known to be linked at human microbiome dysfunction such as cancer, neurodegenerative and metabolic diseases.
IGEN BIOLAB GROUP R&D facilities include technical areas of In vitro cultivation and testing of microorganisms, mass spectrometry-based proteomics technologies to identify, characterize and quantify target proteins in various biological and biomedical samples, metabolomics for detection and quantification of small molecules (metabolites) in biological materials,
IGEN BIOLAB GROUP specializes in protein production, bacterial characterization